Hereditary nonpolyposis colorectal cancer laboratory tests: Difference between revisions
No edit summary |
(Mahshid) |
||
Line 23: | Line 23: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] |
Revision as of 02:02, 27 November 2017
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hereditary nonpolyposis colorectal cancer laboratory tests On the Web |
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer laboratory tests |
FDA on Hereditary nonpolyposis colorectal cancer laboratory tests |
CDC on Hereditary nonpolyposis colorectal cancer laboratory tests |
Hereditary nonpolyposis colorectal cancer laboratory tests in the news |
Blogs on Hereditary nonpolyposis colorectal cancer laboratory tests |
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Laboratory findings consistent with the diagnosis of hereditary nonpolyposis colorectal cancer, may include: positive germline testing for hereditary nonpolyposis colorectal cancer genes (MLH1, MSH2, MSH6, and PMS2), positive EPCAM gene testing, and elevated serum concentration of CEA and CA 125.[1]
Laboratory tests
Laboratory findings consistent with the diagnosis of hereditary nonpolyposis colorectal cancer, may include:
- Positive EPCAM gene
- Positive germline testing (MMR) for hereditary nonpolyposis colorectal cancer genes (MLH1, MSH2, MSH6 and PMS-2)
- Elevated serum concentration of CEA
- Elevated serum concentration of CA-125
References
- ↑ Lynch HT, Drescher K, Knezetic J, Lanspa S (2014). "Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review". Curr Treat Options Oncol. 15 (3): 429–42. doi:10.1007/s11864-014-0293-5. PMID 24827900.